BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38641241)

  • 1. Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review.
    Guo HP; Dang XL; Kang L; Liu C; Liu XW
    World Neurosurg; 2024 Apr; 188():161-169. PubMed ID: 38641241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.
    Yu H; Kong H; Li C; Dong X; Wu Y; Zhuang Y; Han S; Lei T; Yang H
    Transl Cancer Res; 2021 May; 10(5):1975-1983. PubMed ID: 35116520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.
    Schaff L; Nayak L; Grommes C
    Leuk Lymphoma; 2024 Apr; ():1-13. PubMed ID: 38597202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis.
    Lv L; Sun X; Wu Y; Cui Q; Chen Y; Liu Y
    Front Oncol; 2021; 11():707285. PubMed ID: 34277452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.
    Nepal G; Khurana M; Bucheli DH; Bhandari S; Joshi U; Bhagat R; Rehrig JH; Pudasainee P; Shing YK; Ortiz JF; Ojha R; Gajurel BP; Quinonez J; Ruxmohan S; Albert T; Licata S; Stien J
    Neurol Int; 2022 Jan; 14(1):99-108. PubMed ID: 35076567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targets and treatments in primary CNS lymphoma.
    von Roemeling C; Ferreri AJM; Soussain C; Tun HW; Grommes C
    Leuk Lymphoma; 2024 Apr; ():1-13. PubMed ID: 38659230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series.
    Yang C; Cui Y; Ren X; Li M; Yu K; Shen S; Jiang H; Li M; Zhang X; Zhao X; Zhu Q; Lin S
    Front Oncol; 2022; 12():901797. PubMed ID: 35785180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient.
    Zou R; Zhou X; Liu H; Wang P; Xia F; Kang L; Yu L; Wu D; Jin Z; Qu C
    Cancer Res Treat; 2023 Oct; 55(4):1363-1368. PubMed ID: 37321275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
    Narita Y; Nagane M; Mishima K; Terui Y; Arakawa Y; Yonezawa H; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Kitagawa J; Aoi A; Nishikawa R
    Neuro Oncol; 2021 Jan; 23(1):122-133. PubMed ID: 32583848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma.
    Steffanoni S; Batchelor TT
    Curr Opin Neurol; 2021 Dec; 34(6):848-856. PubMed ID: 34581302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
    Sasaki N; Nagane M
    No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma.
    Du S; Fu DB; A Bota D; Kong XT
    CNS Oncol; 2024 Jun; 13(1):2345579. PubMed ID: 38722227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
    Nagane M
    Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma.
    Yang Y; Li Q; Ma J; Kang H; Lin Z; Wang Y; Ma Y; Chen B
    Front Oncol; 2023; 13():1098785. PubMed ID: 37182159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
    Yuan X; Li X; Huang Y; Jin X; Liu H; Zhao A; Zhang W; Qian W; Liang Y
    Front Immunol; 2022; 13():1015081. PubMed ID: 36505470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review.
    Shen J; Liu J
    Front Oncol; 2022; 12():1034668. PubMed ID: 36465385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma.
    Davis DD; Ohana Z; Pham HM
    J Oncol Pharm Pract; 2024 Jan; 30(1):182-188. PubMed ID: 38043933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updates of primary central nervous system lymphoma.
    Wu J; Zhou D; Zhu X; Zhang Y; Xiao Y
    Ther Adv Hematol; 2024; 15():20406207241259010. PubMed ID: 38883164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.